Orexigen Therapeutics Inc

Orexigen Therapeutics — Q3 2015 Earnings Presentation

30 slides from Orexigen Therapeutics's earnings presentation, Nov 5, 2015

  1. Slide 1: 3Q 2015 Conference Call

    3Q 2015 Conference Call November 5, 2015 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its recently approved product, Contrave. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “should,” “intends,” “potential,” “suggests,” “assuming,”

  3. Slide 3: Indication and Important Safety Information

    Indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid conditio

  4. Slide 4: 2H 2015 Focus for Orexigen

    2H 2015 Focus for Orexigen EU and ROW commercialization Continuing US launch success For investor purposes only – not for use in product promotion Acquisition of new assets

  5. Slide 5: Orexigen: An eventful 2015

    Successful US Contrave® (naltrexone HCl / bupropion HCl extended-release) launch, branded market share leader EU Approval for Mysimba™ (naltrexone HCl / bupropion HCl prolonged-release) Balance sheet strengthened $233 million in cash at September 30, 2015 (unaudited) Began earning royalties on US sa

  6. Slide 6: A structured process is advancing toward the best go to market approach

    A structured process is advancing toward the best go to market approach Fully partner out License, but retain key commercial rights Launch via strategic alliances Build de novo South Korea USA EU 31 Australia Brazil Canada China India MENA Mexico Russia Launch Examples Tier 1 markets

  7. Slide 7: Significant ex-US Sales Potential for Contrave / Mysimba

    Country 2014 Sales (M) Peak Year Sales (Year) Mexico $140 $213 (2008) Brazil $120 $164 (2008) Russia $67 $84 (2012) Korea $58 $79 (2008) Australia $56 $58 (2012) MENA* $34 $40 (2010) Canada $14 $36 (2006) India $10 $15 (2010) Significant ex-US Sales Potential for Contrave® / Mysimba™ For investor pu

  8. Slide 8: U.S. Market

    U.S. Market

  9. Slide 9: The overall US obesity prescription drug market shows solid growth

    The overall US obesity prescription drug market shows solid growth Monthly TRx Source: IMS Health NPA Monthly. Note: Orlistat and other medicines not included (c. 7% of market) 1. Includes Qsymia®, Belviq®, Contrave® and Saxenda®’ Branded drugs1 Phentermine 9

  10. Slide 10: US obesity prescription market growing with seasonal patterns

    The overall US obesity prescription drug market is growing with seasonal patterns of utilization +10% 2014 vs 2013 Monthly TRx Source: IMS Health NPA Monthly and Analytics Link +2% 2013 vs 2012 2015 2014 2013 +13% Sep YTD 2015 vs Sep YTD 2014 10

  11. Slide 11: Contrave continues to widen its lead in the US branded market

    Contrave® continues to widen its lead in the US branded market TRx Share Source: IMS Health NPA Monthly Contrave Belviq Qsymia Saxenda 25.0% 27.3% 30.1% 32.4% 33.4% 34.8% 36.2% 37.2% 31,765 36,387 49,047 54,477 56,497 61,076 64,459 63,034 Brand TRx share TRx volume for Contrave 37.8% 62,708 Jan-15 F

  12. Slide 12: New writers of Contrave have increased steadily

    New writers of Contrave® have increased steadily Cumulative writers Source: IMS Health Exponent Weekly, Cumulative totals for each month represented by data from the first week of the newest month. 12

  13. Slide 13: Projections for overall obesity Rx market growth

    Projections for overall obesity Rx market growth Source: IMS NPA Monthly; Orexigen estimates TRx (000) 2013 2014 2017 2016 2015 2018 13

  14. Slide 14: EU Market

    EU Market

  15. Slide 15: Three overarching goals guide European Strategy

    Three overarching goals guide European Strategy Realize maximum value for Orexigen's shareholders 1 Maximize market penetration and Mysimba sales 2 Deploy Orexigen's resources efficiently and effectively 3 Maintain strategic flexibility 15

  16. Slide 16: EU market attributes

    EU market attributes Concentrated obesity specialist community Excess capacity of existing Pharma SFs Patient willingness to pay out-of-pocket Competitive profile of obesity Rx market Skills and capabilities of potential partners Attractive EU market attributes revealed in market research

  17. Slide 17: Significant unmet need and market opportunity

    Significant unmet need and market opportunity Note: Rx eligible: No. of patients calculated based on patient population aged ≥ 18 Obese with a BMI ≥ 30 *Approved Mysimba European markets 1. Orexigen internal estimates for presented to phys. and ov./ob. explicitly diagnosed Source: Orexigen models ba

  18. Slide 18: Continuum of treatment modalities for obesity

    Phentermine Diethyl- propion Benz- pheta- mine Phendi- metrazine Gx Continuum of treatment modalities for obesity GI Lipase Inhibitor GLP-1 Injectable Diet and lifestyle counseling Surgery MOA/Route of Administration Qsymia Belviq Contrave 18

  19. Slide 19: Continuum of treatment modalities for obesity (Mysimba)

    Continuum of treatment modalities for obesity Diet and lifestyle counseling Surgery GLP-1 Injectable Mysimba GI Lipase Inhibitor MOA/Route of Administration 19

  20. Slide 20: Differentiated clinical profile for Mysimba

    Differentiated clinical profile for Mysimba™ MOA Efficacy Safety & Tolerability Metabolic Effect Mysimba supports sustained weight loss via regulation of appetite and reward-driven behavior Individual components approved and available for >30 years for depression, smoking cessation, alcohol and opio

  21. Slide 21: Many EU patients open to taking obesity prescription medicines

    Many EU patients open to taking obesity prescription medicines EU 51 USA2 1. n=500 2. n=300 Source: Orexigen proprietary market research, 2015 – Patient survey 66% Would you take/continue taking a prescription drug for weight reduction? 57% 21

  22. Slide 22: Willingness and ability to pay for obesity prescription medicines

    3 3 GI Lipase Inhibitor1 Willingness and ability to pay for obesity prescription medicines Price range Mysimba willingness/ability to pay surveys1 Market analogies Gx Branded UK reimb. in US $/day 1. Price range for unbranded Gx ~ $ 3.0 – $ 3.6, range for branded Gx ~ $ 3.7 – $ 4.7; 2. Retail price

  23. Slide 23: Obesity clinics in UK and Italy

    Obesity clinics in UK and Italy Source: Obesity Management Association, UK Members map, 2009, http://www.omaorg.com/index.php?option=com_gmapfp&view=gmapfplist&id_perso=1&Itemid=78; Sicob (Italian society for obesity surgery and metabolic diseases), http://www.sicob.org/; Dietologica (collaboration

  24. Slide 24: Obesity Centers most likely to utilize obesity Rx medicines

    Obesity Centers most likely to utilize obesity Rx medicines Focus Integrated centers N/A Surgery centers Behavioral/ medical oriented centers Business Volume Medical Surgical 1. Business impact is combination of prescribing potential and influence; future prescribing potential approximated with Orli

  25. Slide 25: Go to market hypothesis: Sequenced launch most efficient/effective

    Go to market hypothesis: Sequenced launch most efficient/effective Country specific triggers Country specific triggers Country specific triggers Phase I Phase II Phase III Patient GP Specialist Specialty Activation GP Activation Patient Activation Adherence Support GP Awareness Behavior Modification

  26. Slide 26: Go to market hypothesis: ability to leverage strategic alliances

    Go to market hypothesis : ability to leverage strategic alliances Market access Specialist Activation Pharmaco-vigilance / safety Alliance management Patient Activation Supply chain/ Manufacturing Distributors GP Activation Partner functions Brand Marketing Product Supply Pricing / Access Commercial

  27. Slide 27: Go to market hypothesis: GP promotion via revenue sharing

    Go to market hypothesis : general practitioner promotion via revenue sharing 1. Primary detail equivalent Revenue Revenue Share License brand A License brand B N/A Revenue/ Expense 50:50 License brand A Promote brand B N/A Expense Pay per PDE1 N/A Pay per PDE1 Co-promotion Co-marketing CSO 27

  28. Slide 28: Synergistic adjacencies to Contrave / Mysimba

    There are a broad range of synergistic adjacencies to Contrave / Mysimba Variety of close obesity related business adjacencies exist Synergistic new assets could accelerate growth and profitability Other adjacent disease areas include sleep apnea, hepato-renal treatment, orthopedic treatment, women'

  29. Slide 29: Broad and Growing Patent Estate Could Yield Protection Through 2034

    Broad and Growing Patent Estate Could Yield Protection Through 2034 2034 2031 2031 2029 2027 2027 2026 2024 2024/25 Binge Eating (methods) Major Depression (methods) Visceral Fat (methods) Titration / Dose Pack (methods & devices) Tri-layer (methods & compositions) Food Cravings / Titration (methods

  30. Slide 30: Solid Financial Position

    Solid Financial Position Cash Inflows Income from Contrave® / Mysimba™ sales $15 million milestones payable by Takeda in 2016, 2017 Potential sales milestones up to $880M from Takeda over the life of the agreement Other ROW partnership income (e.g. Korea at $7m upfront) Cash Outflows Contrave estima

Orexigen Therapeutics — Q3 2015 Earnings Presentation on 6ix